Moderna Stock Today

MRNA Stock  USD 153.20  13.41  8.05%   


19 of 100


Odds Of Distress

Less than 9

Moderna is trading at 153.20 as of the 29th of May 2024, a -8.05 percent decrease since the beginning of the trading day. The stock's open price was 166.61. Moderna has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. Note, on March 7, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Moderna's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of December 2018
Health Care
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. The company has 383.24 M outstanding shares of which 21.43 M shares are now shorted by private and institutional investors with about 6.26 trading days to cover. More on Moderna

Moving against Moderna Stock

  0.77BMY Bristol Myers SquibbPairCorr
  0.69UNCY Unicycive TherapeuticsPairCorr
  0.65EGRX Eagle PharmaceuticalsPairCorr
  0.65ABBV AbbVie Inc Sell-off TrendPairCorr
  0.59IRWD Ironwood PharmaceuticalsPairCorr
  0.59ALKS Alkermes PlcPairCorr
  0.52DVAX Dynavax TechnologiesPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Moderna Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Moderna's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Moderna or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Moderna's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Moderna's managers, analysts, and investors.
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, NASDAQ Biotechnology, ARCA Biotechnology, Nasdaq 100, NASDAQ 100 Pre, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Moderna report their recommendations after researching Moderna's financial statements, talking to executives and customers, or listening in on Moderna's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Moderna. The Moderna consensus assessment is calculated by taking the average forecast from all of the analysts covering Moderna.
Financial Strength
Based on the key measurements obtained from Moderna's financial statements, Moderna is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. Financial strength of Moderna is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.220.3665
Way Down
Slightly volatile
Total Current Liabilities2.4 BB
Significantly Down
Slightly volatile
Non Current Liabilities Total868 M1.6 B
Way Down
Slightly volatile
Total Assets19.3 B18.4 B
Sufficiently Up
Slightly volatile
Total Current Assets5.8 B10.3 B
Way Down
Slightly volatile
Moderna's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Moderna's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Moderna's financial leverage. It provides some insight into what part of Moderna's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Moderna's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Moderna deploys its capital and how much of that capital is borrowed.
Moderna cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 1.24 B in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Moderna has a current ratio of 2.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Moderna until it has trouble settling it off, either with new capital or with free cash flow. So, Moderna's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Moderna sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Moderna to invest in growth at high rates of return. When we think about Moderna's use of debt, we should always consider it together with cash and equity.

Sale Purchase Of Stock

(1.1 Billion)
Moderna (MRNA) is traded on NASDAQ Exchange in USA. It is located in 200 Technology Square, Cambridge, MA, United States, 02139 and employs 5,600 people. Moderna is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 58.71 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moderna's market, we take the total number of its shares issued and multiply it by Moderna's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Moderna conducts business under Biotechnology sector and is part of Health Care industry. The entity has 383.24 M outstanding shares of which 21.43 M shares are now shorted by private and institutional investors with about 6.26 trading days to cover. Moderna currently holds about 8.35 B in cash with (3.12 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73.
Check Moderna Probability Of Bankruptcy
Ownership Allocation
Moderna maintains a total of 383.24 Million outstanding shares. The majority of Moderna outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Moderna to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Moderna. Please pay attention to any change in the institutional holdings of Moderna as this could imply that something significant has changed or is about to change at the company. Please note that on March 7, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Moderna's common stock.
Check Moderna Ownership Details

Moderna Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Moderna that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moderna's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moderna's value.
InstituionRecorded OnShares
Ubs Asset Mgmt Americas Inc2024-03-31
3.7 M
Capital World Investors2024-03-31
3.6 M
Manufacturers Life Insurance Co2023-12-31
3.5 M
Norges Bank2023-12-31
3.5 M
Banque Pictet & Cie Sa2024-03-31
3.2 M
Northern Trust Corp2023-12-31
Amvescap Plc.2023-12-31
2.9 M
Legal & General Group Plc2023-12-31
2.8 M
Pictet Asset Manangement Sa2024-03-31
2.6 M
Baillie Gifford & Co Limited.2024-03-31
44.7 M
Vanguard Group Inc2024-03-31
39 M
View Moderna Diagnostics

Moderna Historical Income Statement

Moderna Income Statement is one of the three primary financial statements used for reporting Moderna's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Moderna revenue and expense. Moderna Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Moderna's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 1.4 B, whereas Total Revenue is forecasted to decline to about 4.9 B. View More Fundamentals

Moderna Stock Against Markets

Picking the right benchmark for Moderna stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Moderna stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Moderna is critical whether you are bullish or bearish towards Moderna at a given time. Please also check how Moderna's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Holdings Now


Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Moderna Corporate Management

Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
Shannon KlingerChief SecretaryProfile
Brad MillerChief OfficerProfile
Melanie MBAChief OfficerProfile
James MockChief OfficerProfile
Stephane BancelCEO DirectorProfile
John ReyndersChief OfficerProfile
Dave JohnsonChief OfficerProfile

How to buy Moderna Stock?

Before investing in Moderna, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Moderna. To buy Moderna stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Moderna. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Moderna stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Moderna stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Moderna stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Moderna, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Moderna Stock please use our How to Invest in Moderna guide.

Already Invested in Moderna?

The danger of trading Moderna is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Moderna is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Moderna. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Moderna is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Moderna Stock analysis

When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Stocks Directory
Find actively traded stocks across global markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.